Black Diamond Therapeutics Inc (BDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -38,134 | -18,225 | -82,442 | -63,034 | -40,027 |
| Depreciation Amortization | 172 | 86 | 437 | 351 | 236 |
| Accounts payable and accrued liabilities | -1,561 | -1,128 | 597 | -1,033 | 826 |
| Other Working Capital | -4,352 | -4,569 | 3,686 | -239 | -1,480 |
| Other Operating Activity | 7,950 | 2,637 | 11,005 | 11,194 | 6,046 |
| Operating Cash Flow | $-35,925 | $-21,199 | $-66,717 | $-52,761 | $-34,399 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 38 | N/A | 62 | 62 | 95 |
| Purchase Of Investment | -92,032 | -52,234 | -61,887 | -46,101 | 0 |
| Sale Of Investment | 79,000 | 38,500 | 78,171 | 50,136 | 41,886 |
| Investing Cash Flow | $-12,994 | $-13,734 | $16,346 | $4,097 | $41,981 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 25,508 | 4,130 | 71,932 | 71,978 | 51 |
| Financing Cash Flow | $25,508 | $4,130 | $71,932 | $71,978 | $51 |
| Beginning Cash Position | 57,044 | 57,044 | 35,483 | 35,483 | 35,483 |
| End Cash Position | 33,633 | 26,241 | 57,044 | 58,797 | 43,116 |
| Net Cash Flow | $-23,411 | $-30,803 | $21,561 | $23,314 | $7,633 |
| Free Cash Flow | |||||
| Operating Cash Flow | -35,925 | -21,199 | -66,717 | -52,761 | -34,399 |
| Capital Expenditure | N/A | N/A | -33 | -33 | N/A |
| Free Cash Flow | -35,925 | -21,199 | -66,750 | -52,794 | -34,399 |